13 trading days left ! I very much doubt that there is a leak from the FDA. Fear, doubt, nervousness, uncertainty and unprofessionalism have characterized the last 2 trading days.
Those who sell realize a loss - those who buy and hold have extraordinary profit prospects.
"PharmaTher's product pipeline target attractive regulatory incentives for expedited approvals, such as the FDA 505(b)(2) regulatory pathway and orphan drug, fast track and breakthrough designations."
Fast track and breakthrough designations (!!!) from the FDA...why?
Breakthrough Therapy designation is a process designed to expedite the development and review of drugs that are intended to treat a serious condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint(s).
The FDA is obviously very interested in approval, especially as the study results speak for themselves.
There is a saying in Germany: "Those who shy away from risk cannot seize opportunities."
Best luck to all!